Loading stock data…
Oruka Therapeutics, Inc. (ORKA)
$92.49+1.89 (+2.09%)
After Hours$92.49+0.00 (+0.00%)· Last close Jun 29
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oruka Therapeutics, Inc. in the Healthcare sector is trading at $92.49 with a market capitalization of $3.4B. Wall Street consensus targets $142.17 (12 analysts), implying a +53.7% move over the next 12 months. The stock is currently near its 52-week high of $95.32, remaining 126.5% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +53.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.43M↓ | -$34.43M↓ | -$34.10M↓ | -$28.43M↓ | -$25.09M |
| Net Income | -$31.82M↓ | -$29.58M↑ | -$30.28M↓ | -$24.57M↓ | -$21.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.03%
Volume
Today's trading volume
1.33M
Recent News
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
This Menlo Park biotech specializing in antibody therapies saw a notable insider sale following a year of rapid gains in its share price.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.